Supreme Court Allows Abortion Pill By Mail To Continue As Legal Fight Moves Forward

by Emmitt Barry, Worthy News Washington D.C. Bureau Chief

(Worthy News) – The Supreme Court on Thursday allowed continued access to the abortion pill mifepristone by telehealth and mail, temporarily blocking a lower court ruling that would have restored in-person dispensing requirements and limited the drug’s reach into states with abortion restrictions.

The order leaves in place the Food and Drug Administration’s 2023 policy allowing mifepristone to be prescribed remotely and delivered by mail while the lawsuit continues. The case was brought by Louisiana, which argued that the Biden-era FDA rule undermined state abortion laws after the Supreme Court’s 2022 Dobbs decision returned abortion regulation to the states.

The justices did not explain their reasoning. Justices Samuel Alito and Clarence Thomas dissented, warning that the Court’s action undercuts the very federalism principle at the heart of Dobbs. Alito wrote that the case involves what he described as a scheme to weaken the Court’s 2022 ruling, which restored the authority of states to regulate abortion within their own borders.

Thomas also pointed to the Comstock Act, the 19th-century federal law restricting the mailing of abortion-related materials, arguing that the drugmakers could not claim legal injury from an order that made it harder for them to engage in conduct he viewed as unlawful.

The decision pauses a ruling from the 5th U.S. Circuit Court of Appeals, which had said the FDA’s telehealth and mail-order policy should be put on hold while the case proceeds. Louisiana Attorney General Liz Murrill called the Supreme Court’s intervention a troubling rejection of “common-sense” medical oversight.

The FDA, now operating under President Trump, has said it is reviewing the 2023 policy. Notably, the administration did not file a brief defending the rule, leaving mifepristone manufacturers Danco Laboratories and GenBioPro to ask the high court to preserve access.

Democrats and abortion-rights groups celebrated the order but made clear they intend to keep abortion at the center of the midterm elections. Senate Minority Leader Charles Schumer said the order preserves access “for the time being,” while warning that abortion access remains under attack.

Pro-life advocates, meanwhile, argue that mail-order abortion drugs allow abortion providers to bypass state laws and remove critical medical oversight from a procedure that ends unborn life and may carry health risks for women when handled without direct physician supervision.

Mifepristone is typically used with misoprostol in medication abortions. The drug blocks progesterone, causing the uterine lining to break down, while misoprostol induces contractions. Medication abortion now accounts for roughly two-thirds of U.S. abortions, and telehealth abortions have fueled a nationwide increase since the fall of Roe v. Wade, according to abortion-rights research group the Guttmacher Institute.

The Court’s order does not end the case. It keeps the current FDA rules in place while the legal battle continues — and ensures that the fight over abortion pills, state sovereignty, federal drug authority, and the reach of Dobbs will remain one of the nation’s most explosive legal and moral debates.

Latest Worthy News